Search results
Multiple omics levels of chronic lymphocytic leukemia - Cell Death Discovery
Nature· 3 days agoChronic lymphocytic leukemia (CLL) is a lymphoproliferative malignancy characterized by the proliferation of functionally mature but ...
Biotech With 345% Run Posts A 'Clear Win' In Cancer Treatment
Investor's Business Daily· 7 days agoThe company tested its treatment, dubbed NX-5948, in patients with relapsed or refractory forms of ...
EHA 2024: Brukinsa/Venclexta for CLL/SLL lacks control arm in SEQUOIA trial
Clinical Trials Arena via Yahoo Finance· 7 days agoThis trial evaluated the efficacy of AbbVie/Roche's Venclexta (venetoclax) and BeiGene's Brukinsa...
Why Is Penny Stock Mustang Bio Trading Over 190% On Monday? - Mustang Bio (NASDAQ:MBIO)
Benzinga· 7 days agoMB-106 is being developed in a collaboration between Mustang and Fred Hutch Cancer Center to treat...
Nurix Therapeutics (NRIX) Surges 20.6%: Is This an Indication of Further Gains?
Zacks via Yahoo Finance· 5 days agoNurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher...
Coeptis Therapeutics (NASDAQ:COEP) Lowered to Hold at LADENBURG THALM/SH SH
ETF DAILY NEWS· 2 days agoLADENBURG THALM/SH SH lowered shares of Coeptis Therapeutics (NASDAQ:COEP – Free Report) from a strong-buy rating to a hold rating in a report published on Tuesday, Zacks.com reports. Coeptis ...
GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the...
NewMediaWire via Yahoo Finance· 6 days ago10,000-participant randomized Phase 2b study will evaluate and compare GeoVax's multi-antigen,...
EU Adds CAR-T Warning; New Blincyto Indication; Good News in Pancreatic Cancer
MedPage Today· 3 days agoFollowing the FDA's lead, the European Medicines Agency will require labeling for CAR T-cell...
Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket...
Benzinga· 7 days agoShares of Nurix Therapeutics, Inc. NRIX rose sharply in today's pre-market trading after the company announced results from its ongoing clinical trial of NX-5948 in patients with relapsed refractory ...
Nurix Therapeutics CFO Hans van Houte sells $400k in company stock By Investing.com
Investing.com· 3 days agoIn a recent stock transaction, Hans van Houte, Chief Financial Officer of Nurix Therapeutics, Inc....